跳至主要内容
临床试验/JPRN-UMIN000008274
JPRN-UMIN000008274已完成未知

Comparison of the effects of sitagliptin and mitiglinide/voglibose fixed-dose combination tablets on glucose metabolism in patients with uncontrolled type-2 diabetes mellitus. - Comparison of the effects of sitagliptin and mitiglinide/voglibose fixed-dose combination tablets on glucose metabolism

niversity of Occupational and Environmental Health, Japan0 个研究点目标入组 5 人开始时间: 2012年6月27日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
5

研究概览

简要总结

Increasing the dose of STG to 100 mg/day reduces blood glucose levels from midnight to early morning in patients with postprandial hyperglycemia who have HbA1c values of approximately 7%, FPG levels of approximately 120 mg/dL, and postprandial glucose levels >200 mg/dL. In addition, switching to MIT/VOG improves fluctuations in blood glucose levels and postprandial hyperglycemia.

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Patients treated with a sulfonylurea (SU), alfa-glycosidase inhibitor (alfa-GI) or insulin secretagogue (glinide). 2) Patients with diabetic ketoacidosis, diabetic coma/precoma or type-1 diabetes mellitus. 3) Patients with severe infection or serious trauma, or those operated recently or scheduled for surgery. 4) Patients with moderate or severer renal disorder (creatinine level 1.5 mg/dL (men) or 1.3 mg/dL (women)). 5) Patients with liver disorder (AST or ALT level 3 times the normal upper limit). 6) Women who are pregnant or suspected of being pregnant. 7) Women who are breastfeeding. 8) Patients with a history of hypersensitivity to an ingredient of the study drugs. 9) Other patients judged to be ineligible by the investigator.

研究者

发起方
niversity of Occupational and Environmental Health, Japan

相似试验